三鑫医疗(300453) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥272,919,002.98, a decrease of 15.11% compared to ¥321,497,637.25 in the same period last year[4] - The net profit attributable to shareholders was ¥44,785,584.88, down 5.61% from ¥47,447,455.87 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥36,384,675.79, a decline of 22.21% compared to ¥46,771,607.79 in the previous year[4] - The company reported a total profit of CNY 55,017,634.32 for Q1 2023, down 3.8% from CNY 57,334,356.70 in the same quarter last year[20] - Net profit for Q1 2023 was CNY 47,667,602.73, a decline of 5.4% from CNY 50,359,581.15 in Q1 2022[20] - Earnings per share for Q1 2023 were CNY 0.1127, compared to CNY 0.1204 in Q1 2022, reflecting a decrease of 5.7%[20] Cash Flow - The net cash flow from operating activities was -¥34,889,965.06, a significant decrease of 334.65% from ¥14,868,783.06 in the same period last year[4] - Cash inflow from investment activities totaled 25,221,763.58, down from 41,305,600.49, reflecting reduced investment returns[24] - The net cash flow from financing activities increased to 60,845,893.26, compared to 35,765,877.19 in the prior period, showing improved financing capabilities[24] - Cash received from sales of goods and services was 267,165,289.80, down from 332,918,108.44, reflecting a decline in revenue generation[23] - Cash paid for purchasing goods and services was 201,696,949.97, slightly decreased from 205,756,253.81, indicating stable cost management[23] - Cash inflow from other operating activities was 26,006,178.31, an increase from 17,596,721.84, suggesting improved operational efficiency[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,784,933,256.98, a slight decrease of 0.09% from ¥1,786,535,673.29 at the end of the previous year[4] - The equity attributable to shareholders increased by 4.44% to ¥1,123,946,838.23 from ¥1,076,120,829.73 at the end of the previous year[4] - The company's total liabilities as of Q1 2023 amounted to CNY 587,264,070.27, down from CNY 631,130,435.41 in the previous year[19] - Total current assets decreased from ¥689,282,923.80 at the beginning of the year to ¥662,626,342.45 at the end of the period, representing a decline of approximately 3.5%[15] - Total non-current assets increased from ¥1,097,252,749.49 to ¥1,122,306,914.53, showing an increase of approximately 2.3%[16] - Accounts payable decreased from ¥149,663,372.50 to ¥103,996,608.34, a reduction of about 30.5%[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 20,596, with the largest shareholder holding 24.73% of the shares[10] Other Income and Expenses - Other income increased by 204.66% to ¥8,511,533.70, primarily due to an increase in government subsidies received[9] - Investment income rose significantly by 456.05% to ¥1,069,361.58, attributed to increased financial investment returns[9] - Research and development expenses for Q1 2023 were CNY 7,483,945.25, a decrease of 21.1% from CNY 9,481,656.95 in Q1 2022[19] Operational Insights - The company continues to focus on market expansion and new product development strategies to enhance future growth prospects[19] - The company’s first-quarter report was not audited, which may affect the reliability of the financial data presented[25]